Abstract
These studies examined the
in vivo pharmacokinetics and efficacy of five anti-methamphetamine monoclonal antibodies (mAbs,
K
D values from 11 to 250
nM) in rats. While no substantive differences in mAb systemic clearance (
t
1/2
=
6.1–6.9 days) were found,
in vivo function was significantly reduced within 1–3 days for four of the five mAbs. Only mAb4G9 was capable of prolonged efficacy, as judged by prolonged high methamphetamine serum concentrations. MAb4G9 also maintained high amphetamine serum concentrations, along with reductions in methamphetamine and amphetamine brain concentrations, indicating neuroprotection. The combination of broad specificity for methamphetamine-like drugs, high affinity, and prolonged action
in vivo suggests mAb4G9 is a potentially efficacious medication for treating human methamphetamine-related medical diseases.
